FinancialsJust to caution people on financials, Pharmala's year end is in August so we will get the year end in December and that their Q1 3 month ends in November and those are released in January. So I suspect any impact of these contracts may not be seen until Q2 financials which ends in February and are released at the end of April, as the actual clinical trials for some clients have not started and therefore sales may not be there yet from the recently announced contracts. However, Pharmala has been supplying to Australia, Canada and the UK and so there should still be continued growth... which is what we want to see for a positive move forward.
Some people seem overly hyped on the financials on some of these other forums and don't seem to understand the company's financial release dates and when the sales of these contracts will begin to show up. There will be a delay, but as more and more contracts are signed those financials will continue to grow each quarter.
As early investors we are in the early stages of the company's financial growth and by looking ahead will probably continue to have some opportunities to add to positions before the company is actually noticed by the larger institutions and our American friends. One would think names like John Hopkins, Harvard, Mt. Sinai, Texas and Yale would resonate with the American investor community at some point. Pharmala has done some good PR work recently up in Canada, but need to get down into the US to promote the company.